Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
Rhea-AI Summary
Verrica Pharmaceuticals (Nasdaq: VRCA) will report fourth quarter and full year 2025 financial results and provide a corporate update on March 11, 2026.
The company will host a conference call and live webcast at 8:30 a.m. ET; dial-in details, conference ID VERRICA, and a 90-day webcast replay are available on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – VRCA
In the Mar 5 session, VRCA declined 2.44%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Conference participation | Neutral | -3.1% | Participation in TD Cowen healthcare conference with webcast access for investors. |
| Feb 12 | Executive appointment | Positive | -2.3% | Appointment of seasoned Chief Commercial Officer to expand YCANTH commercialization. |
| Feb 09 | Product launch | Positive | +0.0% | Launch of YCANTH in Japan by partner Torii for molluscum contagiosum. |
| Jan 07 | Clinical milestone | Positive | +0.9% | First patient dosed in global Phase 3 program for common warts. |
| Nov 24 | Financing / capital raise | Positive | +12.1% | $50M private placement to repay debt and extend expected cash runway. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive updates (clinical progress, financing, commercial steps) have not always produced consistent upside, with mixed alignment between news tone and next-day price moves.
Over the last several months, Verrica announced a $50 million private placement to retire debt and extend cash runway into mid-2027, a key capital milestone that saw the stock rise over 12%. It then reported initiation of a global Phase 3 program for YCANTH, supported by Torii funding, plus the Japan launch of YCANTH and a new Chief Commercial Officer. Conference participation and commercial build-out have followed. Today’s earnings-date announcement fits into this sequence of commercialization and financing execution.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update.
Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.
A live audio webcast of the call can also be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
